A Phase 1 Study of QLS7402 Injection in Adult Participants With Overweight or Obesity
A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Dose of QLS7402 Injection Administered Subcutaneously in Adult Participants With Overweight or Obesity
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending dose of QLS7402 injection administered subcutaneously in adult participants with overweight or obesity
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This is a first-in-human (FIH), randomized, double-blind, placebo-controlled Phase 1 clinical study of QLS7402 injection, which consists of a single ascending dose (SAD) study in adult participants with overweight or obesity. The study is designed to evaluate the safety, tolerability, PK, and PD of QLS7402 following single subcutaneous administration. In accordance with the dose escalation principle, dose escalation will proceed sequentially from the starting dose to higher dose levels. An individual trial participant will receive only one dose level as a single dose. This study is designed with 5 prespecified escalating dose groups.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Qing wen, Master of Medicine
- Phone Number: +86-13370551767
- Email: wenq0619@126.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1)Willing to participate in this study and provide written informed consent prior to any study-specific procedures; able to understand the study procedures, methods, requirements, and restrictions; and willing to comply with the protocol and complete the study.
- 2) Male and female adults aged between 18 and 55 years, inclusive, at the time of informed consent.
- 3) 27.0 kg/m²≤BMI<35.0 kg/m² at screening.
- 4) Body weight has remained stable for at least 3 months prior to screening(defined as a weight change within ±5%, participant self-reported information is acceptable).
Exclusion Criteria:
- 1) Evidence or history or presence of major diseases, including but not limited to disorders involving the cardiovascular, endocrine (except for primary obesity and mild to moderate hepatic steatosis with normal hepatic function), psychiatric, neurological, gastrointestinal, respiratory, hematological, immunological, urogenital, renal, hepatic, pulmonary, or dermatological systems, or any other condition that, in the judgment of the Investigator, makes the participant unsuitable for this study.
- 2) History of endocrine disorders that may significantly affect body weight (e.g., Cushing's syndrome, hypothalamic obesity, hypothyroidism, or hyperthyroidism), or history of medication-induced obesity, monogenic obesity, or hereditary obesity syndromes.
- 3) History of malignancy.
- 4) Skin conditions and/or tattoos that may interfere with the evaluation of injection site reactions, or abdominal scarring (e.g., due to surgery or burns) that may affect subcutaneous administration; intolerance to subcutaneous injection which, in the investigator's opinion, may preclude study drug administration or local tolerability assessment.
- 5) Difficult venous access (e.g., history of needle phobia or blood phobia), or poor venous conditions that, in the judgment of the Investigator, render the participant unsuitable for enrollment.
- 6) History of or planned any form of bariatric surgery or device-based treatment for obesity during the study period; severe trauma or major surgery within 6 months prior to screening; or planned surgery during the study period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: QLS7402
QLS7402 Injection |
QLS7402 Injection |
|
Placebo Comparator: Placebo
Placebo Control |
Placebo Control |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of participants with treatment-emergent adverse events (TEAEs)
Time Frame: 169 days
|
169 days
|
|
Number of participants with treatment-related adverse events (TRAEs)
Time Frame: 169 days
|
169 days
|
|
Number of participants with serious adverse events (SAEs)
Time Frame: 169 days
|
169 days
|
|
Number of participants with abnormal physical examination, 12-lead ECG and clinical laboratory tests
Time Frame: 169 days
|
169 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The change from baseline in Maximum Plasma Concentration (Cmax)
Time Frame: 3 days
|
3 days
|
|
The change from baseline in Activin E levels
Time Frame: 169 days
|
169 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- QLS7402-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.